State of Alaska Department of Revenue’s Catalyst Pharmaceutical CPRX Stock Holding History

State of Alaska Department of Revenue’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.11M	Sell	67,060 -19,124	-22%	-$564K	0.02%	669
2026 Q1	$2.13M	Sell	86,184 -1,822	-2%	-$43.4K	0.02%	676
2025 Q4	$2.05M	Buy	88,006 +23,076	+36%	+$514K	0.02%	685
2025 Q3	$1.28M	Sell	64,930 -3,341	-5%	-$68.7K	0.01%	938
2025 Q2	$1.48M	Buy	68,271 +6,148	+10%	+$145K	0.02%	855
2025 Q1	$1.51M	Sell	62,123 -1,596	-3%	-$35.9K	0.02%	810
2024 Q4	$1.33M	Buy	63,719 +53	+0.1%	+$1.14K	0.01%	908
2024 Q3	$1.26M	Sell	63,666 -2,214	-3%	-$41K	0.01%	941
2024 Q2	$1.02M	Sell	65,880 -2,158	-3%	-$33.6K	0.01%	994
2024 Q1	$1.08M	Buy	68,038 +6,386	+10%	+$96.2K	0.01%	985
2023 Q4	$1.04M	Sell	61,652 -727	-1%	-$9.94K	0.01%	977
2023 Q3	$729K	Sell	62,379 -1,773	-3%	-$23.7K	0.01%	1139
2023 Q2	$862K	Sell	64,152 -1,413	-2%	-$20.3K	0.01%	1065
2023 Q1	$1.09M	Sell	65,565 -1,105	-2%	-$18.2K	0.01%	923
2022 Q4	$1.24M	Buy	66,670 +1,180	+2%	+$18.2K	0.02%	849
2022 Q3	$840K	Buy	+65,490	New	+$776K	0.01%	1010

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State of Alaska Department of Revenue's CPRX Position: Q2 2026 in Review

State of Alaska Department of Revenue reduced its Catalyst Pharmaceutical (CPRX) stake by 22% in Q2 2026, selling an estimated $564K and leaving 67,060 shares worth $2.11M. The position accounts for 0.02% of the portfolio, ranked #669.

State of Alaska Department of Revenue first reported a position in CPRX in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.13M in Q1 2026. 244 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

State of Alaska Department of Revenue held 67,060 shares of Catalyst Pharmaceutical worth $2.11M as of Q2 2026.
State of Alaska Department of Revenue sold 19,124 Catalyst Pharmaceutical shares in Q2 2026, an estimated $564K.
Catalyst Pharmaceutical made up 0.02% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #669 holding.
State of Alaska Department of Revenue first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 16 quarters since.
State of Alaska Department of Revenue's Catalyst Pharmaceutical position peaked at $2.13M in Q1 2026.
244 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.